Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Every row

Showing 2 of 382 rows for Cholinesterase inhibitor / memantine. One row per study per exposure: a study that tested two different things appears twice, once for each.

Scroll the table sideways to see every column.

Research and outcomes, 2 rows. Every row links to its source.
Exposure Question Direction Outcome measured Design People Effect size, as the source reported it Source
Cholinesterase inhibitor / memantine Medicines Treatment Benefit
why

Observational: 80% of residents were on no anti-dementia drug, so who gets prescribed and who does not may itself track prognosis.

All-cause mortality cohort study 25,358 Adjusted hazard ratios for mortality vs no anti-dementia drug: "HR: 0.826, 95%CI 0.769 to 0.888 for AChEI; 0.857, 95%CI 0.795 to 0.923 for memantine; 0.742, 95%CI 0.640 to 0.861 for AChEI plus memantine" Alzheimer's Research & Therapy 2024
✓ Peer-reviewed PMID 38812028
Cholinesterase inhibitor / memantine Medicines Treatment Benefit
why

Cholinesterase inhibitors, not memantine: -0.39 MMSE points a year against -2.50 with no treatment. The mortality benefit held only in the first year. Registry data with weighting, not a trial.

MMSE decline per year; mortality cohort study 1,095 MMSE change: -0.39 points/year (95% CI -0.96 to 0.18) with cholinesterase inhibitors vs -2.49 (-4.02 to -0.97) with memantine and -2.50 (-4.28 to -0.73) with non-use. Mortality in the first year after diagnosis: adjusted HR 0.66 (95% CI 0.46 to 0.94) Alzheimer's & Dementia 2024
✓ Peer-reviewed PMID 39177108

How this table was built, and where it is weak →

Last updated